此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

卡博替尼和纳武单抗联合放射治疗治疗已扩散至大脑的肾细胞癌患者的研究

2026年11月13日 更新者:Memorial Sloan Kettering Cancer Center

卡博替尼和纳武单抗联合放射治疗转移性肾细胞癌脑转移瘤安全性的 1b 期研究

The purpose of this study is to find out whether the combination of cabozantinib, nivolumab, and radiation therapy is a safe and effective treatment that causes few or mild side effects in people with renal cell cancer that has spread to the brain. The researches will also look at how the study treatment affects the quality of life of participants. They will measure the quality of life by having participants complete questionnaires.

研究概览

研究类型

介入性

注册 (实际的)

2

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

    • New Jersey
      • Basking Ridge、New Jersey、美国、07920
        • Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
      • Middletown、New Jersey、美国、07748
        • Memorial Sloan Kettering Monmouth (All Protocol Activities)
      • Montvale、New Jersey、美国、07645
        • Memorial Sloan Kettering Bergen (All Protocol Activities)
    • New York
      • Commack、New York、美国、11725
        • Memorial Sloan Kettering Cancer Suffolk - Commack (All Protocol Activities)
      • Harrison、New York、美国、10604
        • Memorial Sloan Kettering Westchester (All Protocol Activities)
      • New York、New York、美国、10065
        • Memorial Sloan Kettering Cancer Center (All Protocol Activities)
      • Uniondale、New York、美国、11553
        • Memorial Sloan Kettering Nassau (All Protocol Activities)

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Unresectable advanced or metastatic clear cell or non-clear cell RCC; all histologies acceptable except for chromophobe RCC

  2. Brain metastases present, meeting the following criteria:

    1. At least 1 brain metastasis measuring ≥0.5cm in any dimension (intracranial RANO-BM measurable disease required)
    2. SRS is indicated per treating radiation oncologist
    3. Surgical intervention for brain metastases is not planned
  3. Able to undergo MRI Brain assessments for radiation planning.

  4. Availability of archival tissue that enables the definitive diagnosis of RCC, accompanied by an associated pathology report. If archival tissue cannot be obtained, PI to provide documented confirmation patient can still enroll onto the study. Specimens can be collected by surgical resection or biopsy of the primary tumor or biopsy or resection of a metastatic lesion.

  5. Age ≥18 years

  6. KPS ≥ 80

  7. Adequate hematologic and end organ function, defined by the following laboratory results obtained within 28 days prior to the first study treatment:

    1. ANC ≥ 1500 cells/μL (without granulocyte colony stimulating factor support within 4 weeks prior to Cycle 1, Day 1)
    2. WBC counts ≥ 2500/μL
    3. Absolute lymphocyte count ≥ 500/μL
    4. Platelet count ≥100,000/μL (without transfusion within 4 weeks prior to Cycle 1, Day 1)
    5. Hemoglobin ≥9.0 g/dL o Patients may be transfused or receive erythropoietic treatment to meet this criterion.
  8. AST, ALT, and alkaline phosphatase ≤ 2.5 x ULN, with the following exceptions:

    1. Patients with documented liver metastases: AST and/or ALT ≤ 5 x ULN
    2. Patients with documented liver or bone metastases: alkaline phosphatase ≤ 5 x ULN
  9. Serum bilirubin ≤ 1.5 x ULN

  10. Patients with known Gilbert disease who have serum bilirubin level ≤ 3 x ULN may be- enrolled.

  11. INR and aPTT ≤ 1.5 x ULN

    a. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.

  12. Creatinine ≤ 1.5 x ULN or Calculated Creatinine clearance ≥ 30mL/min by institutional standard measurement

  13. For women who are not postmenopausal (12 months of amenorrhea) or surgically sterile (absence of ovaries and/or uterus): agreement to use two adequate methods of contraception, including at least one method with a failure rate of ≥ 1% per year

  14. If any Grade ≥1 toxicities occurred in relation to prior treatment, patients must have recovered to baseline or ≤ Grade 1 unless adverse events are clinically insignificant or stable on supportive medication if needed.

Exclusion Criteria:

  1. Prior treatment with cabozantinib for RCC

  2. Receipt of any small molecule kinase inhibitor (including investigational) or VEGFtargeted therapy within 2 weeks before the first dose of study treatment

    o 2-week washout period was selected in order to facilitate rapid enrollment and treatment of patients given the target population with active brain metastases.

  3. Patients requiring whole brain radiotherapy (WBRT).

  4. Any prior brain radiotherapy within 28 days prior to enrollment

  5. Incomplete healing from prior radiotherapy as determined by the treating radiation oncologist or treating investigator

  6. Diagnosis of autoimmune condition that may worsen during immune checkpoint blockade, with the following exceptions:

    o Diabetes type I, vitiligo, psoriasis, hypo- or hyperthyroid disease not requiring immunosuppressive treatment are eligible.

  7. Any active or suspected autoimmune disease requiring systemic steroids > 10 mg daily prednisone (or equivalent) or other immunosuppression, except for:

    • those not expected to reoccur
    • Chronic physiologic replacement of ≤10mg prednisone (or equivalent) for treatment of adrenal insufficiency
    • Steroids required for pre-medication reactions
    • Local steroid use is permitted (e.g. intranasal, topical, inhaled, or local steroid injection, i.e. intra-articular)
  8. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures

  9. Uncontrolled hypercalcemia (≥ 1.5 mmol/L ionized calcium or Ca ≥ 12 mg/dL or corrected serum calcium ≥ ULN) or symptomatic hypercalcemia requiring continued use of bisphosphonate therapy or denosumab

  10. Participation in an experimental drug study within 28 days of study enrollment

  11. Pregnant and lactating women

  12. History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins

  13. Significant cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), myocardial infarction within the previous 3 months, unstable arrhythmias, unstable angina, or EF < 50%

    o Patients with known coronary artery disease, congestive heart failure not meeting the above criteria must be on a stable medical regimen that is optimized in the opinion of the treating physician, in consultation with a cardiologist if appropriate.

  14. Uncontrolled hypertension (>140 mm Hg systolic or >90 mm Hg diastolic) despite optimal antihypertensive treatment

  15. QTcF > 500 msec within 28 days before the first dose of study treatment

  16. Major surgical procedure within 14 days prior to Cycle 1, Day 1 or anticipation of need for a major surgical procedure during the course of the study

    o Patients must have completed wound healing from major or minor surgery before first dose of study treatment

  17. History of stroke or transient ischemic attack within 6 months prior to Cycle 1, Day 1

  18. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Cycle 1, Day 1

  19. Evidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation)

    o Clinically significant hematuria, hematemesis, or hemoptysis of >0.5 tsp (2.5ml) of red blood or other history of significant bleeding within 12 weeks before first dose of study treatment.

  20. Clinical signs or symptoms of gastrointestinal obstruction or requirement for routine parenteral hydration, parenteral nutrition, or tube feeding

  21. Evidence of abdominal free air not explained by paracentesis or recent surgical procedure

  22. Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture

  23. Concomitant anticoagulation with coumarin agents, direct thrombin inhibitors, factor Xa inhibitor betrixaban, or platelet inhibitors. Other anticoagulants are allowed.

  24. Abdominal fistula, GI perforation, bowel obstruction, or intra-abdominal abscess within 6 months before first dose of study treatment.

    o Complete healing of intra-abdominal abscess must be confirmed before the first dose of study treatment

  25. Cavitating pulmonary lesion(s) or known endotracheal or endobronchial disease manifestation

  26. Lesions invading or encasing major blood vessels

  27. Uncompensated or symptomatic hypothyroidism

  28. History of solid organ or allogeneic stem cell transplant

  29. Clinically significant active infection including HIV, Hepatitis B, Hepatitis C, acute COVID-19 infection, or other

    • For patients with HIV infection, clinically significant/exclusionary features include: detectable viral load, CD4+ T cell count <300 cells/microL, or history of opportunistic infection
    • For patients with HBV infection, clinically significant/exclusionary features include: HBV surface antigen positivity, detectable HBV DNA by polymerase chain reaction (PCR). Patients with prior HBV infection (HBV core Ab positive, HBV DNA undetectable by PCR, HBV surface antigen negative) are eligible for the study if they are already stable on entecavir or tenofovir
  30. Inability to swallow tablets

  31. Previously identified allergy or hypersensitivity to components of the treatment

  32. Malignancy that requires anti-cancer directed therapy within the last 3 years. Exceptions include those cancers that are considered cured by local therapy (e.g. Basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of breast, bladder, or cervix) or other cancers that have low malignant potential and do not require systemic therapy (e.g. Gleason grade <6 prostate adenocarcinoma)

  33. Patients in whom nivolumab treatment is not otherwise feasible (for example, for financial reasons)

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Cabozantinib and Nivolumab With Radiation Therapy

Patients being newly initiated on cabo/nivo will be started on with cabozantinib 40 mg PO daily and nivolumab 480 mg IV day Q4 weeks

o Dose de-escalation of cabozantinib for toxicity will be allowed per prespecified toxicity dose levels

Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist. Standard institutional regimens such as 18-24 Gy in a single fraction, 24-27 Gy in three fractions, and 25-30 Gy in five fractions are permissible.

Cabozantinib (40 mg PO daily)

Nivolumab (480 mg IV Day 1)

Radiation will be stereotactic radiosurgery, delivered over 1-5 fractions with a total dose of 18-30Gy depending on fractionation schedule per the discretion of the treating radiation oncologist.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
percent of enrolled patients who are able to tolerate treatment
大体时间:56-day

56-day safety monitoring period without unacceptable CNS toxicity. Unacceptable CNS toxicity is defined as any grade ≥3 treatment-emergent neurological disorder, per NCI CTCAE version 5.0 criteria

56-day

次要结果测量

结果测量
措施说明
大体时间
rate of CNS adverse events
大体时间:1 year

CNS adverse events will be reported as a proportion of patients who experience a CNS adverse event of any grade based on CTCAE 5.0

1 year
objective response rate (ORR)
大体时间:1 year

as measured by RANO-BM criteria

1 year

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

合作者

调查人员

  • 首席研究员:Ritesh Kotecha, MD、Memorial Sloan Kettering Cancer Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月10日

初级完成 (估计的)

2027年11月1日

研究完成 (估计的)

2027年11月1日

研究注册日期

首次提交

2023年11月10日

首先提交符合 QC 标准的

2023年11月10日

首次发布 (实际的)

2023年11月15日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月13日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

在美国制造并从美国出口的产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅